Kraj: Kanada
Język: angielski
Źródło: Health Canada
NORETHINDRONE ACETATE; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL
ABBVIE CORPORATION
G03AB04
NORETHISTERONE AND ESTROGEN
1MG; 10MCG; 10MCG
TABLET
NORETHINDRONE ACETATE 1MG; ETHINYL ESTRADIOL 10MCG; ETHINYL ESTRADIOL 10MCG
ORAL
15G/50G
Prescription
CONTRACEPTIVES
Active ingredient group (AIG) number: 0355090001; AHFS:
APPROVED
2022-09-01
_LOLO_ _ _ _(ethinyl estradiol / norethindrone acetate and ethinyl estradiol) _ _Page 1 of 53 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr LOLO® ethinyl estradiol tablets / norethindrone acetate and ethinyl estradiol tablets Tablets, 10 mcg ethinyl estradiol / 1 mg norethindrone acetate and 10 mcg ethinyl estradiol, oral Mfr. Std. Oral Contraceptive ATC Code: G03AB04 AbbVie Corporation 8401 Trans-Canada Highway St-Laurent, Quebec H4S 1Z1 Date of Initial Authorization: DEC 12, 2013 Date of Revision: SEP 14, 2022 Submission Control Number: 263050 _LOLO (ethinyl estradiol / norethindrone acetate and ethinyl estradiol) _ _Page 2 of 53 _ RECENT MAJOR LABEL CHANGES None at the time of the most recent authorization. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics .................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................ 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................... 5 4 DOSAGE AND ADMINISTRATION ................................................................................ 5 4.1 Dosing Considerations .......................................................................................... Przeczytaj cały dokument